habit restaur inc habt hold pt expect anoth posit comp cost
await attract entri analyst stephen anderson full summari
inc atnm buy pt pipelin continu build momentum- combo
anavex life scienc corpor buy pt phase extens studi updat ctad meet go
three year analyst carolin palomequ full summari
inc buy pt earn preview expect solid result bullish outlook support new
corpor event call maxim salesperson inform
women health dinner agrx bioscienc dare kol host palomequ
 mccarthi vendetti thu dec
cover diana ndr ny cfo lui massiani mon
california restaur tour habt host orang counti ca mon
agilysi inc cover klee ndr san francisco ceo ramesh srinivasan wed
corp mcld ndr boston execut chairman russ mcmeekin thu
inc cover klee ndr boston senior director financ suzann lynn director
financ lynn um mon dec
maxim group first annual tmt confer atn ctrl smci
host chokshi klee tue dec
cover klee ndr milwauke madison cfo stan sutula tue dec
cover klee ndr chicago cfo stan sutula wed dec
support new buy-back dividend hike maintain
maintain buy rate price target ahead base
analysi review financi result peer recent hunter point
result schedul novemb market close
follow midterm elect novemb releas vote result
novemb
expect ep ahead initi guidanc last year
ep estim in-lin consensu within
may issu preliminari guidanc base histor compani
expect increas quarterli dividend
increas
forecast ep consensu within manag
initi guidanc ep forecast anoth ep peak
consensu forecast
initi ep guidanc impli new peak ep last two year
releas initi ep guidanc next fiscal year impli anoth year
ep growth instanc two year ago initi ep guidanc
oper ep prior year initi ep guidanc
last year oper ep track
note similar rang outlook anoth year peak ep
impli ep guidanc
identifi quarterli ep result consult compani
led meaning stock declin last week volatil market compar
compani mostli bill project hour believ
allow compani pass higher labor cost custom instanc
previous identifi rate compani sometim
compet water consult project share rebound
two trade day compani report quarterli result indic higher
demand sever industri due part increas concern human health
environ
differ type custom plan increas spend indic
bid opportun expect capit expenditur growth
variou type custom lead new peak ep success
leverag water expertis track record sinc expand
consult area includ environment cleanup work oil ga pipelin design
permit intern develop project
think new peak ep support premium valuat price target
base ep estim target premium
consult peer group multipl account multipl sourc
long-term ep growth on-going new peak ep similar recent dynam
forward pe multipl consist free cash flow lack project
concentr work project year effici execut
short-term project help achiev new peak ep view
click full note
produc fifth consecut blow-out quarter loan
linked-quart total client fund deposit plu off-balance-sheet fund
net interest incom core effici ratio exclud
invest warrant gain manag
increas alreadi strong guidanc
howev share trade friday appar
nim benefit fed rate increas much
previou quarter importantli expens guidanc
mid-teen increas part nim perform
relat libor unusu flat expect better nim
perform
follow sinc except one unjustifi
credit scare downward stock move versu peer
relat manner expens scare explain
emerg previou episod higher revenu lower
introduc ep estim base loan
growth nim loan loss provis averag loan
effici ratio effect tax rate
base new ep estim maintain price target
equat price-to-earnings multipl versu p/
 multipl previou estim modest
premium best-in-class smid-cap bank believ premium
justifi uniqu
remain top pick among smid-cap bank long term
result summari octob post-clos report ep
versu consensu regard yet anoth blow-out quarter see
summari
introduc ep estim base factor mention
page updat earn model share current trade
price-to-earnings multipl base new ep estim
guidanc expens growth mid-teen regard elev
reason main object expens gener revenu higher expens
justifi higher revenu view keep spend money
ep keep increas huge infrastructur build sinc tech wreck
posit bank attract keep custom size
made domin bank world-wide innov ecosystem
made non-replic view earn confer call manag
indic reason time expens spend current
enjoy numer tailwind higher interest rate tax reform bank deregul
view episod prove yet anoth over-react effici
ratio continu improv
reiter buy rate next year expect appreci stock
price price target remain top pick among smid-cap bank
long term due uniqu non-replic franchis growth
implic franchis
click full note
expect anoth posit comp cost
await attract entri
maintain hold rate price target habit restaur
habt ahead releas septemb result tuesday octob
close
although estim comp gain line consensu
model above-consensu ep vs consensu amid easier y/i
lower decemb ep estim consensu
ep estim consensu
howev ep estim unchang consensu
although habt share fallen earli septemb
high prefer wait attract entri point
although estim comp gain line consensu
model above-consensu ep amid easier y/i food cost comparison
habt report june earn rais full-year guidanc earli
august manag said comp recov posit rang
second half comp trend direct open
week comp estim consist outlook estim
relief commod cost particularli beef chicken ad
lower decemb ep estim
ep estim howev ep estim unchang
although lower estim due slightli higher sg
expens expect habt benefit follow factor believ
continu near term
strong unit pipelin expect new unit growth unit per year
company-own serv lead top-lin catalyst
habt support mid-teen revenu growth next year also expect
manag place increas emphasi higher-volum drive-through unit
well focu increasingli lower-cost southern market
return sustain low single-digit comp growth expect manag
initi promot conveni primarili deliveri company-own
locat quality/valu premium limited-time-off digit deal
innov expand breakfast test start support comp growth
least slightli pace
benign food cost model food cost deflat remain quarter
translat food cost inflat outlook flat full-year vs
guidanc estim benign food cost outlook add much
annual ep upsid next four quarter
opportun margin expans expect labor product
measur revamp open close procedur design improv
labor product mitig labor cost increas futur quarter
valuat unchang price target believ upsid on-going
initi balanc potenti risk particularli higher
labor cost price target habt base combin three
methodolog forward price-to-earnings ratio target ep estim
forward ev/ebitda ratio forward sale ratio
combin methodolog arriv price target
click full note
phase extens studi updat ctad
meet go three year
anavex present updat data phase studi anavex ad
clinic trial alzheim diseas ctad meet phase
extens phase week valid clinic respons seen week
per updat importantli anavex continu show favor safeti
toler ae sae
patient cohort higher plasma concentr anavex
maintain alzheim diseas co-op studi activ
daili live inventori adcs-cl score p-valu higher
mental state examin mmse score vs patient cohort lower
biomark impact result exclud patient
comt biomark patient popul demonstr anavex
clinic signific improv function cognit score
conclus data support observ safeti
efficaci mark well design on-going phase
patient trial anavex studi show concentration-
depend respons exploratori function cognit
endpoint new ad genom biomark variant comt
enabl target therapi patient like
benefit treatment anavex phase studi extend
week patient comt biomark anavex respons
assess week extens studi data confirm result
seen week see page
phase trial alzheim diseas ad double-blind random
placebo-control safeti efficaci trial anavex ad
exclud patient comt
variant less like benefit treatment patient
random two differ dose anavex placebo enrol
earli alzheim patient primari secondari endpoint assess safeti
cognit function efficaci measur adas-cog adcs-adl
cdr-sb trial begin clinic site australia expand north
america trial current enrol estim top-line data readout
click full note
pipelin continu build momentum- combo
actinium held confer call discuss next program
 nr venetoclax venclexta relapsed/refractori acut
venetoclax hma ldac demonstr overal respons rate
r/r aml set preclin data demonstr synergi
actimab venetoclex addit acitmab alreadi demonstr
clinic respons secondari aml thu rational combin
md updat call follow discuss kol actimab
program target acceler program instead patient
program go small follow directli pivot program
look toward american societi hematolog decemb
expect actinium busi compani continu
build momentum heme-onc space abstract due
ventoclax hma actimab lintuzumab combo make sens aml
lethal aggress form blood treatment option patient
inelig intens chemotherapi aml lowest surviv rate blood
cancer aml patient relaps overal surviv rate aml
follow treatment dismal juli submit snda fda
venetoclax inhibitor use combin either hypomethyl agent
hma low-dos cytarabin ldac treatment-nav patient base result
two trial trial complet remiss cr rate combin drug
either azacitidin decitabin trial cr achiev
combin ldac venetoclax hma lead orr r/r aml
monotherapi overal respons rate r/r aml venetoclax single-
agent hma
overal data suggest still room improv two-third
patient invari relaps stop respond discontinu use venetoclax
older patient bmt true cure still typic option
venetoclax also prolong myelosupress make reach bmt even
challeng preclin work actimab venetoclax suggest potenti
synergi occur via degrad therebi provid rational evalu
combin r/r aml anti-apoptot protein upregul
refractori aml mediat resist venetoclax studi expect
initi explor combin actimab venetoclax hma success
combin could potenti provid meaning clinic impact r/r aml patient
beyond venetoclax hma ldac
venetoclax hma actimab trial design phase studi follow trial
design pt patient infus actimab combin
venetoclax patient receiv cycl studi endpoint includ determin
maximum toler dose actimab-a overal respons rate orr disease-
free surviv overal surviv
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
